CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual.

PubWeight™: 1.10‹?› | Rank: Top 10%

🔗 View Article (PMC 2453227)

Published in PLoS One on July 23, 2008

Authors

Djin-Ye Oh1, Heiko Jessen, Claudia Kücherer, Konrad Neumann, Nari Oh, Gabriele Poggensee, Barbara Bartmeyer, Arne Jessen, Axel Pruss, Ralf R Schumann, Osamah Hamouda

Author Affiliations

1: Institute of Microbiology and Hygiene, Charité University Medical Center, Berlin, Germany. doh@tuftsmedicalcenter.org

Articles citing this

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55

Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet (2010) 1.25

Zinc-finger nucleases for somatic gene therapy: the next frontier. Hum Gene Ther (2011) 1.11

How HIV changes its tropism: evolution and adaptation? Curr Opin HIV AIDS (2009) 0.98

Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology (2008) 0.97

Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92

Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia. AIDS Res Hum Retroviruses (2013) 0.88

Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32. AIDS (2015) 0.85

Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis. PLoS One (2012) 0.81

Stem cell-based approaches to treating HIV infection. Curr Opin HIV AIDS (2011) 0.80

Use of the heteroduplex mobility assay and cell sorting to select genome sequences of the CCR5 gene in HEK 293T cells edited by transcription activator-like effector nucleases. Genet Mol Biol (2013) 0.79

TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection. Virology (2010) 0.78

Genetic diversity and linkage disequilibrium in the chemokine receptor CCR2-CCR5 region among individuals and populations. Cytokine (2013) 0.77

Risk of HIV Infection and Lethality Are Decreased in CCR5del32  Heterozygotes: Focus Nosocomial Infection Study and Meta-analysis. Acta Naturae (2012) 0.77

HIV infection and host genetic mutation among injecting drug-users of northeastern states of India. J Health Popul Nutr (2010) 0.77

Coregulation of HIV-1 dependency factors in individuals heterozygous to the CCR5-delta32 deletion. AIDS Res Ther (2013) 0.76

Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR5∆32/∆32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction. Sci Rep (2015) 0.76

Clinical Applications of Genome Editing to HIV Cure. AIDS Patient Care STDS (2016) 0.75

Coreceptor usage of Chinese HIV-1 and impact of X4/DM transmission clusters among recently infected men who have sex with men. Medicine (Baltimore) (2016) 0.75

Articles cited by this

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91

Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science (1996) 15.63

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62

Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol (1992) 10.25

HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11

Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21

Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83

Advantage of rare HLA supertype in HIV disease progression. Nat Med (2003) 4.08

Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) Science (1998) 3.86

Human genes that limit AIDS. Nat Genet (2004) 3.80

Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet (1997) 2.77

CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. JAMA (1998) 2.25

HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med (1997) 2.15

HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet (1997) 2.11

HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet (1997) 1.95

Biology of CCR5 and its role in HIV infection and treatment. JAMA (2006) 1.84

Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81

Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69

CCR5 genotype and resistance to vertical transmission of HIV-1. J Acquir Immune Defic Syndr (1999) 1.67

Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol (2006) 1.62

Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr (2001) 1.48

Prevalence of CCR5Delta32 polymorphism in long-term survivors of heart transplantation. Transpl Immunol (2006) 1.42

The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37

HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS (2008) 1.34

HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr (2002) 1.33

Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32

A functional toll-like receptor 8 variant is associated with HIV disease restriction. J Infect Dis (2008) 1.29

Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol (2006) 1.24

Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr (2001) 1.21

Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr (2005) 1.14

Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol (2006) 1.11

Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet (2002) 1.10

Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J Virol (2001) 1.10

Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS (2004) 1.08

Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS (2003) 1.07

Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.03

A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression. J Immunol Methods (2001) 1.00

An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3'A allele. AIDS (1999) 0.98

Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point. J Infect Dis (2002) 0.96

The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. Br J Haematol (2000) 0.96

Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med (2007) 0.95

Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment. AIDS (2006) 0.86

Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians. Hum Immunol (2007) 0.84

HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32. AIDS (1999) 0.81

Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus. J Infect Dis (2003) 0.80

Articles by these authors

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09

Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69

Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol (2005) 4.38

Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36

HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52

Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis (2005) 3.39

Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35

Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii. J Immunol (2006) 3.24

Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol (2008) 3.24

IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood (2009) 3.14

Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem (2003) 3.13

HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 2.72

Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50

Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis (2002) 2.33

TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A (2007) 2.28

Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem (2004) 2.18

Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol (2007) 2.14

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14

Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS One (2007) 2.05

Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis (2009) 2.03

Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A (2005) 1.95

HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol (2010) 1.90

Impact of platform switching on marginal peri-implant bone-level changes. A systematic review and meta-analysis. Clin Oral Implants Res (2014) 1.85

Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82

Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity (2003) 1.81

Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80

Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79

A prospective time-course study on serological testing for human immunodeficiency virus, hepatitis B virus and hepatitis C virus with blood samples taken up to 48 h after death. J Med Microbiol (2011) 1.77

Ten years of clinical results with a tissue-engineered pulmonary valve. Ann Thorac Surg (2011) 1.70

Influenza A(H1N1)v in Germany: the first 10,000 cases. Euro Surveill (2009) 1.68

High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. J Mol Med (Berl) (2003) 1.66

The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65

Influenza vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: a secondary data analysis based on billing data of the German associations of statutory health insurance physicians. Dtsch Arztebl Int (2010) 1.65

Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis (2011) 1.64

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis (2015) 1.61

Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58

Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS (2005) 1.54

Estimating the regional distribution of men who have sex with men (MSM) based on Internet surveys. BMC Public Health (2009) 1.51

Mid-term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure. Ann Thorac Surg (2007) 1.50

Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50

Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol (2005) 1.49

Contamination during production of heater-cooler units by Mycobacterium chimaera potential cause for invasive cardiovascular infections: results of an outbreak investigation in Germany, April 2015 to February 2016. Euro Surveill (2016) 1.48

Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PLoS One (2011) 1.45

Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J Infect Dis (2006) 1.43

Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis (2006) 1.42

The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37

Streptococcal M protein: a multipotent and powerful inducer of inflammation. J Immunol (2006) 1.36

External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis (2011) 1.34

Cytokine induction by purified lipoteichoic acids from various bacterial species--role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release. Eur J Immunol (2002) 1.34

The role of lipopolysaccharide-binding protein in modulating the innate immune response. Microbes Infect (2006) 1.32

Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol (2004) 1.31

HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology (2013) 1.30

Transmission and long-term stability of compensated CD8 escape mutations. J Virol (2008) 1.29

Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One (2010) 1.29

Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis (2003) 1.28

A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol (2007) 1.27

The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27

The denominator problem: estimating MSM-specific incidence of sexually transmitted infections and prevalence of HIV using population sizes of MSM derived from Internet surveys. BMC Public Health (2009) 1.26

The effect of hospital size and surgical service on case cancellation in elective surgery: results from a prospective multicenter study. Anesth Analg (2011) 1.25

Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A (2009) 1.25

Immune responses induced by spirochetal outer membrane lipoproteins and glycolipids. Immunobiology (2008) 1.23

HIV serosorting among HIV-positive men who have sex with men is associated with increased self-reported incidence of bacterial sexually transmissible infections. Sex Health (2011) 1.22

Varicella vaccination coverage of children under two years of age in Germany. BMC Public Health (2010) 1.21

Understanding recent increases in the incidence of sexually transmitted infections in men having sex with men: changes in risk behavior from risk avoidance to risk reduction. Sex Transm Dis (2006) 1.20

Triptans reduce the inflammatory response in bacterial meningitis. J Cereb Blood Flow Metab (2002) 1.20

Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. J Orthop Res (2011) 1.19

Tissue responses to an experimental calcium phosphate cement and mineral trioxide aggregate as materials for furcation perforation repair: a histological study in dogs. Clin Oral Investig (2006) 1.18

Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol (2006) 1.18

A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS (2009) 1.18

Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun (2005) 1.15

Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr (2005) 1.14

Effect of Nigella sativa (black seed) on subjective feeling in patients with allergic diseases. Phytother Res (2003) 1.12

Surface microhardness of enamel after different home bleaching procedures. Dent Mater (2006) 1.10

Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis (2009) 1.10

Acylated cholesteryl galactoside as a novel immunogenic motif in Borrelia burgdorferi sensu stricto. J Biol Chem (2003) 1.10

Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther (2006) 1.09

Interferon-gamma differentially modulates the release of cytokines and chemokines in lipopolysaccharide- and pneumococcal cell wall-stimulated mouse microglia and macrophages. Eur J Neurosci (2002) 1.09

The broader context of antibiotic resistance: zinc feed supplementation of piglets increases the proportion of multi-resistant Escherichia coli in vivo. Int J Med Microbiol (2013) 1.09